Pharmacological profile of the 5-HT(2C) receptor agonist WAY-163909; therapeutic potential in multiple indications

  • CNS Drug Rev. 2006 Fall-Winter;12(3-4):167-77. doi: 10.1111/j.1527-3458.2006.00167.x.
John Dunlop  1 ,  Karen L Marquis ,  H K Lim ,  Louis Leung ,  John Kao ,  Cynthia Cheesman ,  Sharon Rosenzweig-Lipson
Affiliations
PMID: 17227285 DOI: 10.1111/j.1527-3458.2006.00167.x
Abstract

The 5-HT(2C) receptor subtype has been implicated in a wide variety of conditions including obesity, anxiety, depression, obsessive compulsive disorder, schizophrenia, migraine and erectile dysfunction and as a consequence has received considerable attention as a target for drug discovery. Here we review the pharmacological, pharmacokinetic and toxicological profile of WAY-163909 {(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole}, a novel 5-HT(2C) receptor selective agonist. Consistent with a potential therapeutic utility in obesity, schizophrenia and depression WAY-163909 was found to have robust dose-dependent effects in animal models of obesity, psychotic-like behavior or depression.

Products